Clinical Trials List
2025-04-04 - 2029-12-07
Phase I/II
Recruiting3
ICD-10C34.90
Malignant neoplasm of unspecified part of unspecified bronchus or lung
ICD-10C34.91
Malignant neoplasm of unspecified part of right bronchus or lung
ICD-10C34.92
Malignant neoplasm of unspecified part of left bronchus or lung
ICD-10C7A.090
Malignant carcinoid tumor of the bronchus and lung
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9162.9
Malignant neoplasm of bronchus and lung, unspecified
-
Trial Applicant
NOVARTIS (TAIWAN) CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Kung-Chu Ho Division of Nuclear Medicine
- 柯皓文 Division of Hematology & Oncology
- Chih-Hung Chen Division of Hematology & Oncology
- 枋岳甫 Division of Thoracic Medicine
- Ping-Chih Hsu Division of Hematology & Oncology
- Cheng-Ta Yang Division of Hematology & Oncology
- 林定佑 Division of Hematology & Oncology
- Wen-Cheng Chang Division of Hematology & Oncology
- Chien-Ying Liu Division of Hematology & Oncology
- Jia-Shiuan Ju Division of Hematology & Oncology
- Chih-Liang Wang Division of Hematology & Oncology
- 邱立忠 Division of Thoracic Medicine
- Tzu-Pei Su Division of Nuclear Medicine
- 黃宗楨 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
7 participants
-
Global
200 participants
